Abstract:
This research compared eight established or novel enzyme prodrug gene therapy combinations in vitro in order to identify combinations that have specific propensity to destroy endothelial cells (HUVEC or HMEC-1) rather than tumour cells (T24). Combinations with low or absent local bystander effect were of particular interest due to their potential for reduced extracellular toxicity, and thus decreased systemic toxicity.